Open an account

Bio Green Med Solution

BGMS · NASDAQ

$0.96+$0.0162 (+1.72%)TodayMarket closed ·
Prev close $0.9438

About BGMS

Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.

Employees
0
Headquarters
KUALA LUMPUR, New Jersey
Listed
Jan 1, 1996
Sector
Health Care
Industry
Biotechnology
Website
bgmsglobal.com

BGMS key statistics

Market cap
6.36M
Price-earnings ratio
0.00
Dividend yield
1.00%
Average volume
33.38K
Volume
23.82K
Open price
$0.9157
High today
$0.9884
Low today
$0.8715
52 Week high
$2.80
52 Week low
$0.5664

Bio Green Med Solution (BGMS) at a glance

Bio Green Med Solution (BGMS) last traded at $0.96, with a market cap of 6.36M, a price-to-earnings ratio of 0.00 and a dividend yield of 1.00%.

Today the stock has traded between $0.8715 and $0.9884. The current price is 10.2% above the day's low and 2.9% below its high.

Volume so far is 23.82K shares, below the average of 33.38K shares a day.

Over the past year Bio Green Med Solution has ranged from $0.5664 to $2.80, and now sits 18% of the way up that range.

Bio Green Med Solution met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY24 it reported -$43.20 per share against an estimate of -$135.86.

BGMS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 43.4% on average.

  1. Q4 FY22: reported -$2,160.00 per share against an estimate of -$1,771.74
  2. Q1 FY23: reported -$1,692.00 per share against an estimate of -$2,435.75
  3. Q2 FY23: reported -$1,584.00 per share against an estimate of -$1,848.23
  4. Q3 FY23: reported -$1,764.00 per share against an estimate of -$1,334.15
  5. Q4 FY23: reported -$1,495.20 per share against an estimate of -$1,442.69
  6. Q1 FY24: reported -$544.80 per share against an estimate of -$1,161.58
  7. Q2 FY24: reported -$172.80 per share against an estimate of -$351.29
  8. Q3 FY24: reported -$43.20 per share against an estimate of -$135.86

BGMS news

  • Press releasePRNewswire

    Are BZH, LNTH, BGMS Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    ACT NOW: The M&A Class Action Firm Is Investigating the Merger-- ATKR, BZH, BGMS and CBAN

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releasePRNewswire

    Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ACA, BGMS, NIMU, and FSEA

  • Press releasePRNewswire

    Are GBTG, BGMS, SUNE, ESPR Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SUNE, NUVL, CCRN, and BGMS

  • Dylan Berman

    Bio Green Med Solution Surges 172% After Announcing Deal to Acquire Malaysia Waste Tech Company

Similar companies

Companies in the same industry as Bio Green Med Solution

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.